135 related articles for article (PubMed ID: 16215760)
1. Pentane-1,5-diol as a percutaneous absorption enhancer.
Faergemann J; Wahlstrand B; Hedner T; Johnsson J; Neubert RH; Nyström L; Maibach H
Arch Dermatol Res; 2005 Dec; 297(6):261-5. PubMed ID: 16215760
[TBL] [Abstract][Full Text] [Related]
2. Effect of pentane-1,5-diol and propane-1,2-diol on percutaneous absorption of terbinafine.
Evenbratt H; Faergemann J
Acta Derm Venereol; 2009; 89(2):126-9. PubMed ID: 19325994
[TBL] [Abstract][Full Text] [Related]
3. A comparison of pentane-1,5-diol to other diols for use in dermatology.
Sundberg JJ; Faergemann J
Expert Opin Investig Drugs; 2008 Apr; 17(4):601-10. PubMed ID: 18363524
[TBL] [Abstract][Full Text] [Related]
4. Bioavailability, antipsoriatic efficacy and tolerability of a new light cream with mometasone furoate 0.1%.
Korting HC; Schöllmann C; Willers C; Wigger-Alberti W
Skin Pharmacol Physiol; 2012; 25(3):133-41. PubMed ID: 22353786
[TBL] [Abstract][Full Text] [Related]
5. Comparative potency of formulations of mometasone furoate in terms of inhibition of 'PIRHR' in the forearm skin of normal human subjects measured with laser doppler velocimetry.
Kulhalli P; Chevli T; Karnik R; Sheth M; Mulgaonkar N
Indian J Dermatol Venereol Leprol; 2005; 71(3):170-4. PubMed ID: 16394405
[TBL] [Abstract][Full Text] [Related]
6. The in vitro activity of pentane-1,5-diol against aerobic bacteria. A new antimicrobial agent for topical usage?
Faergemann J; Hedner T; Larsson P
Acta Derm Venereol; 2005; 85(3):203-5. PubMed ID: 16040402
[TBL] [Abstract][Full Text] [Related]
7. A comparison of once-daily application of mometasone furoate 0.1% cream compared with twice-daily hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients who failed to respond to hydrocortisone: mometasone furoate study group.
Lebwohl M
Int J Dermatol; 1999 Aug; 38(8):604-6. PubMed ID: 10487451
[No Abstract] [Full Text] [Related]
8. The antimycotic activity in vitro of five diols.
Faergemann J; Fredriksson T
Sabouraudia; 1980 Dec; 18(4):287-93. PubMed ID: 7455861
[TBL] [Abstract][Full Text] [Related]
9. Assessment of topical corticosteroid activity using the vasoconstriction assay in healthy volunteers.
Görne RC; Greif C; Metzner U; Wigger-Alberti W; Elsner P
Skin Pharmacol Physiol; 2007; 20(3):133-40. PubMed ID: 17191036
[TBL] [Abstract][Full Text] [Related]
10. Modulation of dihydroavenanthramide D release and skin penetration by 1,2-alkanediols.
Heuschkel S; Wohlrab J; Schmaus G; Neubert RH
Eur J Pharm Biopharm; 2008 Sep; 70(1):239-47. PubMed ID: 18514497
[TBL] [Abstract][Full Text] [Related]
11. Low drug load, high retention mometasone furoate cream with polyglyceryl - 3 oleate as a chemical enhancer: Formulation development, in vivo and in vitro evaluation and molecular mechanisms.
Jia W; Pang Y; Zhao C; Cai Y; Zhang Y; Liu C; Fang L
Int J Pharm; 2024 Jun; 659():124284. PubMed ID: 38810934
[TBL] [Abstract][Full Text] [Related]
12. In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new.
Kerscher MJ; Hart H; Korting HC; Stalleicken D
Int J Clin Pharmacol Ther; 1995 Apr; 33(4):187-9. PubMed ID: 7620686
[TBL] [Abstract][Full Text] [Related]
13. Different approaches for improving skin accumulation of topical corticosteroids.
Senyiğit T; Padula C; Ozer O; Santi P
Int J Pharm; 2009 Oct; 380(1-2):155-60. PubMed ID: 19635541
[TBL] [Abstract][Full Text] [Related]
14. Superior nuclear receptor selectivity and therapeutic index of methylprednisolone aceponate versus mometasone furoate.
Mirshahpanah P; Döcke WD; Merbold U; Asadullah K; Röse L; Schäcke H; Zollner TM
Exp Dermatol; 2007 Sep; 16(9):753-61. PubMed ID: 17697148
[TBL] [Abstract][Full Text] [Related]
15. Mometasone furoate-loaded cold processed oil-in-water emulsions: in vitro and in vivo studies.
Raposo S; Tavares R; Gonçalves L; Simões S; Urbano M; Ribeiro HM
Drug Deliv; 2015; 22(4):562-72. PubMed ID: 24559480
[TBL] [Abstract][Full Text] [Related]
16. Transdermal iontophoretic delivery of hydrocortisone from cyclodextrin solutions.
Chang SL; Banga AK
J Pharm Pharmacol; 1998 Jun; 50(6):635-40. PubMed ID: 9680073
[TBL] [Abstract][Full Text] [Related]
17. Application of hydrotropy to transdermal formulations: hydrotropic solubilization of polyol fatty acid monoesters in water and enhancement effect on skin permeation of 5-FU.
Takahashi K; Komai M; Kinoshita N; Nakamura E; Hou XL; Takatani-Nakase T; Kawase M
J Pharm Pharmacol; 2011 Aug; 63(8):1008-14. PubMed ID: 21718283
[TBL] [Abstract][Full Text] [Related]
18. Glycols: The ubiquitous solvent for dermal formulations.
Yu HL; Goh CF
Eur J Pharm Biopharm; 2024 Mar; 196():114182. PubMed ID: 38224756
[TBL] [Abstract][Full Text] [Related]
19. [Effects of penetration enhancers on in vitro percutaneous absorption and amount retained in skin of paeonol, dictamnine, fraxinellone and glycyrrhetinic acid in Liangfu cream].
Wang S; Zhu W; Ou S; Guan Y; Chen L; Yang M
Zhongguo Zhong Yao Za Zhi; 2009 Jul; 34(14):1778-82. PubMed ID: 19894505
[TBL] [Abstract][Full Text] [Related]
20. The influence of alcohol, propylene glycol and 1,2-pentanediol on the permeability of hydrophilic model drug through excised pig skin.
Duracher L; Blasco L; Hubaud JC; Vian L; Marti-Mestres G
Int J Pharm; 2009 Jun; 374(1-2):39-45. PubMed ID: 19446757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
